Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

	of entity ute Mining Limited	
ABN 39 09	7 088 689	
We (t	the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Performance Rights
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	Performance Rights: Issued - 1,926,629
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Performance Rights issued are in accordance with the 2017 Resolute Mining Limited Performance Rights Plan. The number of Performance Rights which will vest at the vesting date is based on performance against the hurdles outlined below. Each Performance Right that vests will convert (upon exercise) to one fully paid ordinary share for nil cash consideration. The Performance Rights will be

⁺ See chapter 19 for defined terms.

performance tested as at 30 June 2020 and will vest subject to meeting the following performance hurdles:

- 75% of such Performance Rights will be subject to the relative total shareholder return performance hurdles. In determining performance against the shareholder return performance hurdle; and
- 25% of such Performance Rights will tested against the reserve/resource growth over a 3-year period.

Performance Rights that do not vest will lapse immediately.

Further details on the terms of the Performance Rights can be found on pages 14 to 16 of Resolute's Financial Report for the year ended 30 June 2017.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No. Performance Rights do not rank equally with existing fully paid ordinary shares from the date of issue and do not participate in any dividends or distributions.

Any fully paid shares issued on the conversion of Performance Rights will rank equally in all respects with existing issued ordinary fully paid shares.

5 Issue price or consideration

No cash consideration

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The 1,926,629 Performance Rights issued represent the Long Term Incentive component of remuneration for executive employees relating to the 3-year period ending 30 June 2020.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h	No
	in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	
6с	Number of *securities issued without security holder approval under rule 7.1	
6d	Number of *securities issued with security holder approval under rule 7.1A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	
6f	Number of *securities issued under an exception in rule 7.2	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	

⁺ See chapter 19 for defined terms.

- 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements
- 7 *Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

The Performance Rights were issued on 17 October 2017.

8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)

Number	⁺ Class
741,477,595	Shares

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
4,309,629	Performance Rights (Level 1) with a vesting period ending on 30 June 2018.
470,478	Performance Rights (Level 2) with a vesting period ending on 30 June 2018.
2,823,734	Annual grant of Performance Rights with a vesting period ending on 30 June 2019.
400,000	Special grant of Performance Rights with a vesting period ending on 30 June 2018.
600,000	Special grant of

	Performance Rights with a vesting period ending on 30 June 2019.
1,000,000	Special grant of Performance Rights with a vesting period ending on 30 June 2020.
1,926,629	Annual grant of Performance Rights with a vesting period ending on 30 June 2020.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) The Directors may from time to time determine dividends to be distributed to members according to their rights and interests.

Performance Rights do not participate in any dividends or distributions. However the number of Performance Rights which will vest at the vesting date based on performance against the total shareholder return performance hurdle will be adjusted to allow for any capital returns and dividends during the vesting period.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A

⁺ See chapter 19 for defined terms.

-6	Mill heldings on different	NT / A
16	Will holdings on different registers (or subregisters) be aggregated for calculating	N/A
	entitlements?	
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
10	Closing date for receipt of	NI/A
19	acceptances or renunciations	N/A
20	Names of any underwriters	N/A
	,	
	Amount of any underwriting fee	NI/A
21	or commission	N/A
22	Names of any brokers to the	N/A
22	issue	IV/A
22	Fee or commission payable to the	N/A
23	broker to the issue	IN/A
24	Amount of any handling fee	N/A
	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	behalf of security holders	
25	If the issue is contingent on	N/A
	security holders' approval, the	
	date of the meeting	
26	Date entitlement and acceptance	N/A
20	form and offer documents will be	IN/A
	sent to persons entitled	
27	If the entity has issued options, and the terms entitle option	N/A
	holders to participate on	
	exercise, the date on which	
	notices will be sent to option	
	holders	

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
	3 - Quotation of securitie red only complete this section if you are ap Type of *securities (tick one)	
(a)	*Securities described in Part	. 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entiti	es that have ticked box 34(a)	
Addi	tional securities forming a nev	v class of securities
Tick to docum	indicate you are providing the informatents	tion or
35	1 1	securities, the names of the 20 largest holders of the the number and percentage of additional *securities

+ See chapter 19 for defined terms.

36	1 1	securities, a distribution schedule of the additional mber of holders in the categories
37	A copy of any trust deed for t	he additional ⁺ securities
Entiti	es that have ticked box 34(b)	
38	Number of *securities for which *quotation is sought	
39	⁺ Class of ⁺ securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security)	

Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

Number	+Class

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Company Secretary	Date: 17/10/2017
Print name:	Amber Stanton	

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	735,452,008
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with 	4 September 2017– 4,494,827
 issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period 	
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	
"A"	739,946,835

Step 2: Calculate 15% of "A"	
"B"	0.15
Multiply "A" by 0.15	110,992,025
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
 Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	27 October 2016 – 1,457,867 ordinary shares 4 November 2016 – 72,893 ordinary shares 17 October 2017 – 1,926,629 Performance Rights with a vesting period ending on 30 June 2020
"C"	3,457,389
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	110,992,025
Note: number must be same as shown in Step 2	
Subtract "C"	3,457,389
Note: number must be same as shown in	

Total ["A" x 0.15] – "C"

Step 3

04/03/2013 Appendix 3B Page 11

107,534,636[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.